Elsevier

Neuroscience Letters

Volume 440, Issue 3, 8 August 2008, Pages 197-201
Neuroscience Letters

Decreased serum neurotrophin 3 in chronically medicated schizophrenic males

https://doi.org/10.1016/j.neulet.2008.04.027Get rights and content

Abstract

There is evidence that major psychiatric disorders such as schizophrenia (SZ) are associated with deregulation of synaptic plasticity with downstream alterations of neurotrophins. NT3 is an important neurotrophin in the central nervous system, and performs key biological functions, such as promoting the survival, differentiation, and plasticity of neurons. NT3 has a central role in the early neuronal development; enhancing the survival of dopaminergic neurons, suggesting possible involvement in the physiopathology of dopamine related neuropsychiatric disorders such as SZ. Variations in the NT3 gene increase the risk of SZ. Three groups of chronically medicated DSM-IV patients with SZ, on treatment with clozapine (n = 12), haloperidol (n = 12), risperidone (n = 12) and 10 healthy controls had 5 ml blood samples collected by venipuncture. NT3 serum levels were assessed using sandwich-ELISA and were significantly lower in SZ patients (p < 0.005) when compared to either controls. These findings suggest that the NT3 signaling system may play a role in the pathophysiology of SZ and might be related to the course of illness or to treatment variables. Longitudinal studies are warranted.

Section snippets

Acknowledgements

Clarissa Severino Gama is funded by CNPq (PDE #200310/2007-0), Brazil, and Endeavour Awards Programme (#539/2008), Australia.

References (52)

  • M. Hattori et al.

    Association of neurotrophin-3 gene variant with severe forms of schizophrenia

    Biochem. Biophys. Res. Commun.

    (1995)
  • T.L. Huang et al.

    Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients

    J. Psychiatr. Res.

    (2006)
  • F. Kapczinski et al.

    Allostatic load in bipolar disorder: implications for pathophysiology and treatment

    Neurosci. Biobehav. Rev.

    (2008)
  • P.C. Maisonpierre et al.

    NT-3, BDNF, and NGF in the developing rat nervous system: parallel as well as reciprocal patterns of expression

    Neuron

    (1990)
  • P.C. Maisonpierre et al.

    Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations

    Genomics

    (1991)
  • A. Palomino et al.

    Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients

    Schizophr. Res.

    (2006)
  • W. Pan et al.

    Permeability of the blood–brain barrier to neurotrophins

    Brain Res.

    (1998)
  • J.F. Poduslo et al.

    Permeability at the blood–brain and blood–nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF

    Mol. Brain Res.

    (1996)
  • L. Qian et al.

    Brain-derived neurotrophic factor and risk of schizophrenia: an association study and meta-analysis

    Biochem. Biophys. Res. Commun.

    (2007)
  • B. Rost et al.

    Monocytes of allergics and non-allergics produce, store and release the neurotrophins NGF, BDNF and NT-3

    Regul. Pept.

    (2005)
  • A. Schutte et al.

    The endogenous survival promotion of axotomized rat corticospinal neurons by brain-derived neurotrophic factor is mediated via paracrine, rather than autocrine mechanisms

    Neurosci. Lett.

    (2000)
  • E. Shimizu et al.

    Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls

    Neurosci. Lett.

    (2003)
  • Y.L. Tan et al.

    Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics

    Neurosci. Lett.

    (2005)
  • J.C. Walz et al.

    Serum neurotrophin-3 is increased during manic and depressive episodes in bipolar disorder

    Neurosci. Lett.

    (2007)
  • X.Y. Zhang et al.

    Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics

    J. Psychiatr. Res.

    (2007)
  • K. Agerman et al.

    Differential influence of BDNF and NT3 on the expression of calcium binding proteins and neuropeptide Y in vivo

    Neuroreport

    (2003)
  • Cited by (0)

    View full text